Pharmaceuticals and Life Sciences Pharmaceuticals and Life Sciences

MindMed in its $249-million underwritten public offering

On November 3, 2025, Mind Med, a clinical stage biopharmaceutical company developing novel products to treat brain health disorders, announced it closed approximately a $249-million underwritten public offering which includes a full exercise of the underwriter’s option to purchase additional...

Lead Office: Vancouver Date Announced: November 3, 2025 Value: $249 million

AmacaThera in its licensing agreement with Pacira Biosciences for US$230 million

On November 4, 2025, AmacaThera announced that it signed an exclusive global licensing agreement with Pacira Biosciences for up to US$230 million, validating its tunable drug delivery platform. AmacaThera is a leading developer of next-generation hydrogel-based drug delivery solutions. Using a...

Lead Office: Toronto Date Announced: November 4, 2025 Value: US$230 million

Aspect Biosystems in its $115-million Series B funding round

On January 8, 2025, Aspect Biosystems announced the closing of its $115-million Series B funding round led by Dimension, with participation from existing and new investors including Novo Nordisk, Radical Ventures, an undisclosed leading global investment firm, InBC, Pallasite Ventures, Pangaea...

Lead Office: Vancouver Date Announced: January 8, 2025 Value: $115 million

Amplitude Ventures and Lifearc Ventures in connection with Fluid Biomed's $27-million financing

On December 16, 2024, Fluid Biomed announced the close of its $27-million Series A funding round co-led by Amplitude Ventures and an undisclosed investor, with follow-up investment from LifeArc Ventures. Fluid Biomed plans to use the funds to fuel the development of its innovative stent for brain...

Lead Office: Calgary Date Announced: December 16, 2024 Value: $27 million

KisoJi in its raising of $57-million Series B financing

On December 6, 2024, KisoJi announced it raised $57 million of Series B financing. This round was co-led by Investissement Québec and Lumira Ventures. The round also saw participation from Fonds de solidarité FTQ, adMare BioInnovations and Remiges Ventures. The company plans on utilizing the...

Lead Office: Montreal Date Announced: December 6, 2024 Value: $57 million

Ernst & Young as court-appointed monitor to IntelGenx and its sale to Atai

On October 2, 2024, in the context of their successful restructuring proceedings under the Companies’ Creditors Arrangement Act, IntelGenx Corp. and IntelGenx Technologies Corp. (together, IntelGenx) entered into a transaction with Atai Life Sciences AG (Atai) whereby Atai acquired all of the...

Lead Office: Montreal Date Announced: October 2, 2024 Value: --

Nomic Bio in its raising of $42 million in a Series B financing round

On September 17, 2024, Nomic Bio announced its closing of a $42-million Series B financing round. This round was led by a U.S.-based life-sciences-focused investor and also saw participation from Amplitude Ventures, AVANT BIO, Lux Capital, Real Ventures and SR One. Through this funding, the...

Lead Office: Toronto Date Announced: September 17, 2024 Value: $42 million

ParaPRO LLC in its US$89.5-million asset sale to Cipher Pharmaceuticals

On July 29, 2024, Cipher Pharmaceuticals Inc. announced the signing of a definitive asset purchase agreement with ParaPRO LLC (ParaPRO) and the closing of the acquisition of the global product rights for Natroba™ (Spinosad), as well as the commercial sales team in the United States for total...

Lead Office: Toronto Date Announced: July 29, 2024 Value: US$ 89.5 million

Amplitude Ventures in its closing of its $263 million venture capital fund

On May 28, 2024, Amplitude Ventures announced it closed $263 million in its second venture capital fund for precision medicine. Through this fund, the company plans to continue investing in new precision medicine companies with an interest in biology and artificial intelligence. This fund is...

Lead Office: Montreal Date Announced: May 28, 2024 Value: $263 million

Fusion Pharmaceuticals in its acquisition by AstraZeneca

On March 19, 2024, Fusion Pharmaceuticals announced that it entered into a definitive agreement to be acquired by AstraZeneca for a transaction value of approximately US$2.4 billion. Through this acquisition, AstraZeneca is taking a significant leap towards its goal of revolutionizing cancer...

Lead Office: Toronto Date Closed: -- Value: US$2.4 billion